A Phase 1/2 interventional study of Lenalidomide and Sunitinib in Renal Cell Carcinoma, sponsored by Celgene. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-25.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies testing sunitinib in Carcinoma, Renal Cell — 3 open to participants now, 6 under way, none of them phase 3. Sunitinib · Carcinoma, Renal Cell.
Among the 78 studies testing sunitinib in Carcinoma, Renal Cell, this one is the 57th largest by enrollment, is one of 10 that started in 2009, is one of 6 in phase 1/2, and was the 38th registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.
Browse Carcinoma, Renal Cell studies →3 of the 78 studies testing sunitinib in Carcinoma, Renal Cell are open now, in 2 countries. Recruiting first, the newest first:
State University of New York at Buffalo · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 65+
First Affiliated Hospital, Sun Yat-Sen University
Ages 18–75
By country, each count listing its studies:
Sunitinib: first FDA approval 2006 (SUTENT), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 52 · Phase 3 3 · Phase 4 5
First in 2004; this study’s year is marked. 10 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 43 across 1,566 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 33 across the 78 interventional studies. Of the 60 that completed or were terminated, 32 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 78 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb: 5 open now, 8 under way, 2 of them phase 3. Of 32 finished, 16 (50%) have results posted.
Among the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb, this one is the 30th largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2009, is one of 5 in phase 1/2, and was the 8th registered.
Bristol-Myers Squibb’s Carcinoma, Renal Cell studies by the year they started, since 2003.
2 of the studies testing sunitinib in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00715442M.D. Anderson Cancer CenterPre-Surgical Sutent in Renal Cell Carcinoma (RCC) | 2026-12-04 |
| NCT03541902M.D. Anderson Cancer CenterCabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 78 studies testing sunitinib in Carcinoma, Renal Cell, from their registry updates:
Among Bristol-Myers Squibb’s 42 in Carcinoma, Renal Cell:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to determine the maximum tolerated dose, safety, and effectiveness of lenalidomide (CC-5013) administered in combination with sunitinib as treatment for patients with renal cell carcinoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received an oral dose of lenalidomide MTD (mg) capsule administered in combination with a single dose of sunitinib 37.5 mg on days 1-21 of each 21-day cycle
Drug: Lenalidomide · Drug: Sunitinib
Participants received an oral daily dose of lenalidomide on Days 1 to 21 in combination with a single oral daily dose of sunitinib 37.5 mg on days 1 to 14 or days 1 to 21 of each 21-day cycle
Drug: Lenalidomide · Drug: Sunitinib
Lenalidomide MTD mg by mouth (PO) daily for Days 1- 21 in combination
Also known as: CC-5013, Revlimid
Sunitinib 37.5 mg PO daily on days 1-21 of each 21-day cycle in Cohort A or on days 1-14 in Cohorts F and G
Also known as: Sutent
Phase 1: Maximum Tolerated Dose (MTD)
The MTD of lenalidomide in combination with sunitinib was defined as the highest dose level at which no more than 1 out of 6 participants experienced a dose limiting toxicity (DLT). Dose limiting toxicities were: • Inability to deliver Lenalidomide in Cycle 1 due to a drug-related toxicity resulting in: * Grade (GR) 3 or 4 non-hematological toxicity lasting for ≥ 14 days * Febrile neutropenia * Gr 4 neutropenia lasting for ≥ 7 days * Gr 4 thrombocytopenia The occurrence of one of the above drug-related toxicities resulting in a clinical and/or laboratory assessment being done within 7 days following the initial finding to examine the participants for resolution of the toxicity. Lack of resolution of the toxicities was considered a DLT. If ≤ 7 doses of lenalidomide or Sunitinib were missed in Cycle 1 due to non-drug related event, the participant data was to be included in the evaluation of dose escalation.
Time frame: Within 21 days of first dose of treatment
Phase 2: Tumor Response Rate According to Response Evaluation Criteria In Solid Tumors (RECIST 1.1)
Tumor response was to be evaluated every 3 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response was to be defined by RECIST 1.1 criteria: * Complete response-disappearance of all lesions * Partial response-30% decrease in the sum of diameters of target lesions from baseline * Stable disease-neither shrinkage nor increase of lesions. * Progressive Disease-20% increase in the sum of diameters of target lesions from nadir.
Time frame: After at least 3 cycles of treatment
Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) While on Both Lenalidomide and Sunitinib
Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participants health, including laboratory test values, regardless of etiology. Serious adverse event (SAE) = any AE which: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. TEAE = any AE occurring or worsening on or after the first treatment with any study drug. Related = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 4.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death
Time frame: First day of study drug to within 28 days after the last dose of the last study drug; The duration of exposure to lenalidomide and sunitinib was 7.0 to 327 and 7.0 to 328 days respectively
Phase 1 : Tumor Response Rate According to RECIST 1.1
Tumor response was evaluated every 3 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response was evaluated using the Response Criteria Evaluation in Solid Tumors (RECIST 1.1) criteria: Treatment response includes both complete response and partial response * Complete response-disappearance of all lesions * Partial response-30% decrease in the sum of diameters of target lesions from baseline * Stable disease-neither shrinkage nor increase of lesions * Progressive Disease-20% increase in the sum of diameters of target lesions from nadir
Time frame: Every 3 cycles; up to month 25
Progression Free Survival (PFS)
Progression-free survival was defined as the time from the start of study drug therapy to the first observation of disease progression or death due to any cause, whichever came first.
Time frame: Day 1 of study drug to disease progression or death
Duration of Response
Duration of response was defined as the time from the initial response date to progressive disease (PD) for participants who achieved an objective confirmed complete response (CR) or partial response (PR)
Time frame: Day 1 of initial response date to progressive disease
Overall Survival (OS)
Overall survival was defined as the time from the start of study drug therapy to death.
Time frame: Day 1 of study drug to death
| Milestone | Cohort A: Lenalidomide 10mg and Sunitinib 37.5 mg | Cohort F: Lenalidomide 10mg and Sunitinib 37.5mg | Cohort G: Lenalidomide 15mg and Sunitinib 37.5mg |
|---|---|---|---|
| Started | 5 | 7 | 4 |
| Completed | 0 | 0 | 0 |
| Not completed | 5 | 7 | 4 |
| Withdrew: Adverse event | 2 | 1 | 2 |
| Withdrew: Disease progression | 1 | 5 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Physician decision and disease related | 1 | 0 | 1 |
The MTD of lenalidomide in combination with sunitinib was defined as the highest dose level at which no more than 1 out of 6 participants experienced a dose limiting toxicity (DLT). Dose limiting toxicities were: • Inability to deliver Lenalidomide in Cycle 1 due to a drug-related toxicity resulting in: * Grade (GR) 3 or 4 non-hematological toxicity lasting for ≥ 14 days * Febrile neutropenia * Gr 4 neutropenia lasting for ≥ 7 days * Gr 4 thrombocytopenia The occurrence of one of the above drug-related toxicities resulting in a clinical and/or laboratory assessment being done within 7 days following the initial finding to examine the participants for resolution of the toxicity. Lack of resolution of the toxicities was considered a DLT. If ≤ 7 doses of lenalidomide or Sunitinib were missed in Cycle 1 due to non-drug related event, the participant data was to be included in the evaluation of dose escalation.
| mg | Cohort F: Lenalidomide 10mg and Sunitinib 37.5mg |
|---|---|
| Phase 1: Maximum Tolerated Dose (MTD) | 10 |
Tumor response was to be evaluated every 3 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response was to be defined by RECIST 1.1 criteria: * Complete response-disappearance of all lesions * Partial response-30% decrease in the sum of diameters of target lesions from baseline * Stable disease-neither shrinkage nor increase of lesions. * Progressive Disease-20% increase in the sum of diameters of target lesions from nadir.
No measurements were reported for this outcome.
Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participants health, including laboratory test values, regardless of etiology. Serious adverse event (SAE) = any AE which: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. TEAE = any AE occurring or worsening on or after the first treatment with any study drug. Related = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 4.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death
| participants | Cohort A: Lenalidomide 10mg and Sunitinib 37.5 mg | Cohort F: Lenalidomide 10mg and Sunitinib 37.5mg | Cohort G: Lenalidomide 15mg and Sunitinib 37.5mg |
|---|---|---|---|
| Participants with at least 1 TEAE | 5 | 7 | 4 |
| Participants with at least 1 serious TEAE | 3 | 4 | 2 |
| ≥ 1 TEAE leading to stopping lenalidomide | 2 | 2 | 2 |
| ≥ 1 TEAE leading to stopping sunitinib | 2 | 2 | 2 |
| ≥ 1 TEAE -> dose reduction/interrruption of Len | 5 | 6 | 4 |
| ≥ 1 TEAE dose reduction/interrruption of Sunitinib | 5 | 5 | 3 |
| Participants with ≥1 TEAE related to lenalidomide | 5 | 7 | 4 |
| Participants with ≥1 TEAE related to Sunitinib | 5 | 7 | 4 |
| ≥ 1 NCI CTC Gr 3 or higher TEAE | 5 | 6 | 4 |
| ≥ 1 NCI CTC Gr 3 or higher related to lenalidomide | 4 | 5 | 4 |
| ≥ 1 NCI CTC Gr 3 or higher related to Sunitinib | 4 | 5 | 4 |
| ≥ 1 serious TEAE related to lenalidomide | 2 | 2 | 0 |
| ≥ 1 serious TEAE related to sunitinib | 1 | 2 | 2 |
Tumor response was evaluated every 3 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response was evaluated using the Response Criteria Evaluation in Solid Tumors (RECIST 1.1) criteria: Treatment response includes both complete response and partial response * Complete response-disappearance of all lesions * Partial response-30% decrease in the sum of diameters of target lesions from baseline * Stable disease-neither shrinkage nor increase of lesions * Progressive Disease-20% increase in the sum of diameters of target lesions from nadir
| participants | Cohort A: Lenalidomide 10mg and Sunitinib 37.5 mg | Cohort F: Lenalidomide 10mg and Sunitinib 37.5mg | Cohort G: Lenalidomide 15mg and Sunitinib 37.5mg |
|---|---|---|---|
| Complete Response | 0 | 0 | 0 |
| Partial Response | 1 | 0 | 0 |
| Stable Disease | 1 | 3 | 3 |
Progression-free survival was defined as the time from the start of study drug therapy to the first observation of disease progression or death due to any cause, whichever came first.
No measurements were reported for this outcome.
Duration of response was defined as the time from the initial response date to progressive disease (PD) for participants who achieved an objective confirmed complete response (CR) or partial response (PR)
No measurements were reported for this outcome.
Overall survival was defined as the time from the start of study drug therapy to death.
No measurements were reported for this outcome.
Collected over Phase 1 Only. From the date of the first study drug dose to within 28 days after the study drug treatment was discontinued.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A | — | 3/5 (60%) | 5/5 (100%) |
| Cohort F | — | 4/7 (57.1%) | 7/7 (100%) |
| Cohort G | — | 2/4 (50%) | 4/4 (100%) |
| Event | Cohort A | Cohort F | Cohort G |
|---|---|---|---|
| Atrial FibrillationCardiac disorders | 0/5 | 0/7 | 1/4 |
| PancreatitisGastrointestinal disorders | 0/5 | 0/7 | 1/4 |
| AnaemiaBlood and lymphatic system disorders | 1/5 | 0/7 | 0/4 |
| LeukopeniaBlood and lymphatic system disorders | 1/5 | 0/7 | 0/4 |
| NeutropeniaBlood and lymphatic system disorders | 1/5 | 0/7 | 0/4 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/5 | 0/7 | 0/4 |
| AstheniaGeneral disorders | 1/5 | 0/7 | 0/4 |
| Device related infectionInfections and infestations | 1/5 | 0/7 | 0/4 |
| Urinary Tract InfectionInfections and infestations | 1/5 | 0/7 | 0/4 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 1/5 | 1/7 | 0/4 |
| Event | Cohort A | Cohort F | Cohort G |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/5 | 3/7 | 2/4 |
| FatigueGeneral disorders | 3/5 | 7/7 | 4/4 |
| NauseaGastrointestinal disorders | 4/5 | 4/7 | 3/4 |
| DysgeusiaNervous system disorders | 4/5 | 4/7 | 1/4 |
| LeukopeniaBlood and lymphatic system disorders | 2/5 | 1/7 | 3/4 |
| AnaemiaBlood and lymphatic system disorders | 3/5 | 3/7 | 1/4 |
| VomitingGastrointestinal disorders | 3/5 | 3/7 | 2/4 |
| DehydrationMetabolism and nutrition disorders | 3/5 | 0/7 | 0/4 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 3/5 | 2/7 | 0/4 |
| DizzinessNervous system disorders | 3/5 | 1/7 | 2/4 |
Safety Population includes all participants who received at least one dose of study drug.
| Age, Continuous(years) | Cohort A: Lenalidomide 10mg and Sunitinib 37.5 mg | Cohort F: Lenalidomide 10mg and Sunitinib 37.5mg | Cohort G: Lenalidomide 15mg and Sunitinib 37.5mg | Total |
|---|---|---|---|---|
| Mean | 55.0 ± 18.84 | 57.1 ± 4.88 | 57.3 ± 5.62 | 56.5 ± 10.56 |
| Age, Customized(participants) | Cohort A: Lenalidomide 10mg and Sunitinib 37.5 mg | Cohort F: Lenalidomide 10mg and Sunitinib 37.5mg | Cohort G: Lenalidomide 15mg and Sunitinib 37.5mg | Total |
|---|---|---|---|---|
| ≤65 years | 4 | 7 | 4 | 15 |
| >65 years | 1 | 0 | 0 | 1 |
| Sex: Female, Male(Participants) | Cohort A: Lenalidomide 10mg and Sunitinib 37.5 mg | Cohort F: Lenalidomide 10mg and Sunitinib 37.5mg | Cohort G: Lenalidomide 15mg and Sunitinib 37.5mg | Total |
|---|---|---|---|---|
| Female | 2 | 4 | 2 | 8 |
| Male | 3 | 3 | 2 | 8 |
| Race/Ethnicity, Customized(participants) | Cohort A: Lenalidomide 10mg and Sunitinib 37.5 mg | Cohort F: Lenalidomide 10mg and Sunitinib 37.5mg | Cohort G: Lenalidomide 15mg and Sunitinib 37.5mg | Total |
|---|---|---|---|---|
| Caucasian (White) | 4 | 6 | 4 | 14 |
| Black or African American | 1 | 0 | 0 | 1 |
| Unknown | 0 | 1 | 0 | 1 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Cohort A: Lenalidomide 10mg and Sunitinib 37.5 mg | Cohort F: Lenalidomide 10mg and Sunitinib 37.5mg | Cohort G: Lenalidomide 15mg and Sunitinib 37.5mg | Total |
|---|---|---|---|---|
| 0 = fully active | 4 | 4 | 4 | 12 |
| 1 = restricted activity but ambulatory | 1 | 3 | 0 | 4 |
| 3 (Limited Self-Care) | 0 | 0 | 0 | 0 |
| 4 (Completely Disabled) | 0 | 0 | 0 | 0 |
Ran from Sep 2009 to primary completion in Oct 2011, 25 months.
Results were first posted in Dec 2014, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenalidomide · Sunitinib